Ultragenyx Pharmaceutical Inc. vs UnitedHealth Group Incorporated — Stock Comparison
Ultragenyx Pharmaceutical Inc. (RARE) and UnitedHealth Group Incorporated (UNH) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
UnitedHealth Group Incorporated narrowly edges Ultragenyx Pharmaceutical Inc. on Q·Score (6.1 vs 5.4 out of 10), led by Quality (5.9 vs 2.2) and Growth (5.1 vs 3.4). Ultragenyx Pharmaceutical Inc. scores higher on Valuation, reflecting stronger P/E and price-target positioning. Analyst consensus targets imply greater upside for RARE (+89.7%) than for UNH (+2.2%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $52.05 is 90% above current price.
⚠ currently unprofitable (-91% margin).
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
Fundamentals
Frequently Asked Questions
RARE vs UNH: which stock scores better overall?
Based on Q·Score, UnitedHealth Group Incorporated (UNH) scores 6.1/10 versus Ultragenyx Pharmaceutical Inc. (RARE) at 5.4/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: RARE or UNH?
UnitedHealth Group Incorporated (UNH) scores higher on Growth (5.1/10 vs 3.4/10). Ultragenyx Pharmaceutical Inc. reports revenue growth (-2.2% YoY) while UnitedHealth Group Incorporated reports (2.0% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is RARE or UNH more attractively valued?
Ultragenyx Pharmaceutical Inc. (RARE) scores higher on Valuation (9/10 vs 6.5/10). RARE trades at 28.4× P/E versus UNH at 19.2×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about RARE vs UNH?
There are 19 analysts covering RARE with a consensus price target of $52.05, and 26 analysts covering UNH with a consensus target of $409.77. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: RARE or UNH?
UnitedHealth Group Incorporated (UNH) scores higher on Quality (5.9/10 vs 2.2/10). Net profit margin: RARE at -90.9%, UNH at 2.7%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: RARE or UNH?
Ultragenyx Pharmaceutical Inc. (RARE) scores higher on Financial Health (5.4/10 vs 5.3/10). Market beta: RARE at 0.38, UNH at 0.65. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of RARE and UNH?
Ultragenyx Pharmaceutical Inc. (RARE) has a market capitalisation of $2.7B, while UnitedHealth Group Incorporated (UNH) has a market cap of $364.1B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do RARE or UNH pay dividends?
RARE does not currently pay a dividend, while UNH pays a dividend yield of 2.31%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →